More and more new oral small molecules are entering the dermatologic arena. A relevant advantage over biologics is their oral bioavailability.
Small molecule inhibitors are organic compounds with different chemical structures and molecular weights ranging from 500 to 900 Da. As Prof. Lone Skov (Herlev-Gentofte Hospital, Denmark) pointed out, they have a simple structure and are easy to produce; hence, they are much cheaper than biologics [1,2]. Small molecules can easily diffuse across cell membranes to reach intracellular sites. Once the inhibitor enters the cells, it affects various other molecules and reduces cellular levels of specific proteins . In comparison to larger molecules such as monoclonal antibodies, they have the advantage of possible oral administration and ease of combination with other treatments .
TYK2 inhibitor promising in psoriasis
Prof. Lars Iversen (Aarhus University Hospital, Denmark) pointed ou...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Biologics: biosimilars and lifestyle Next Article
Insights into pathogenesis of AD define novel therapeutic targets »
Table of Contents: WCD 2019
Treating Psoriasis in 2019
Atopic Dermatitis – What is New
Dermal Reactions to Systemic Drugs
Lupus Erythematosus Today
Small Molecules – What to Expect
Optimising the Management of Keloids
Malignant Melanoma – Advances in Management
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.